MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

MediWound Ltd. (NASDAQ:MDWD) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $17.91 and traded as low as $17.41. MediWound shares last traded at $17.57, with a volume of 27,761 shares trading hands.

Analyst Ratings Changes

Several analysts have commented on the stock. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective (up from $31.00) on shares of MediWound in a research note on Friday, November 21st. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.50.

MediWound Trading Down 3.2%

The company’s 50-day moving average is $17.92 and its 200 day moving average is $17.91. The stock has a market capitalization of $225.07 million, a PE ratio of -9.25 and a beta of 0.13.

Hedge Funds Weigh In On MediWound

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in MediWound during the 4th quarter worth about $26,000. BNP Paribas Financial Markets raised its stake in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in MediWound in the fourth quarter valued at approximately $109,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.